Neurological manifestations of coronavirus disease (COVID-19) have increasingly been reported since the onset of the pandemic. Herein, we report a relatively new presentation. A patient in the convalescence period following a febrile illness with lower respiratory tract infection (fever, myalgia, nonproductive cough) presented with generalized disabling myoclonus, which is phenotypically suggestive of brainstem origin, along with additional truncal cerebellar ataxia. His neurology work-ups, such as brain MRI, electroencephalography, serum autoimmune and paraneoplastic antibody testing, were normal. His CT chest scan revealed right lower lung infiltrates, and serological and other laboratory testing did not show evidence of active infection. COVID-19 titers turned out to be strongly positive, suggestive of post-COVID-19 lung sequelae. He responded partially to antimyoclonic drugs and fully to a course of steroids, suggesting a para- or postinfectious immune-mediated pathophysiology. Myoclonusataxia syndrome appears to be a neurological manifestation of COVID-19 infection, and knowledge regarding this phenomenon should be increased among clinicians for better patient care in a pandemic situation.
Citations
Citations to this article as recorded by
A case of suspected autoimmune encephalopathy with involuntary movements and cognitive dysfunction post‐COVID‐19 Yosuke Tenpaku, Naoki Mabuchi, Takahiro Kawase, Hideki Oguro, Hiroshi Tatsumi, Masayuki Satoh Psychiatry and Clinical Neurosciences Reports.2024;[Epub] CrossRef
Opsoclonus Myoclonus Ataxia Syndrome Due to SARS-CoV-2 Josef Finsterer, Fulvio A. Scorza Neuro-Ophthalmology.2023; 47(1): 1. CrossRef
Myoclonus in patients with COVID‐19: Findings of autoantibodies against brain structures in cerebrospinal fluid Isa Lindqvist, Janet L. Cunningham, Jan Mulder, Amalia Feresiadou, Elham Rostami, Johan Virhammar, Eva Kumlien European Journal of Neurology.2023; 30(10): 3142. CrossRef
Temporal Changes in Brain Perfusion in a Patient with Myoclonus and Ataxia Syndrome Associated with COVID-19 Kenta Osawa, Atsuhiko Sugiyama, Akiyuki Uzawa, Shigeki Hirano, Tatsuya Yamamoto, Masahiko Nezu, Nobuyuki Araki, Hiroki Kano, Satoshi Kuwabara Internal Medicine.2022; 61(7): 1071. CrossRef
Post‐infectious cerebellar ataxia following COVID‐19 in a patient with epilepsy Sidhartha Chattopadhyay, Judhajit Sengupta, Sagar Basu Clinical and Experimental Neuroimmunology.2022; 13(4): 323. CrossRef
Persistent neurological manifestations in long COVID-19 syndrome: A systematic review and meta-analysis Rizaldy Taslim Pinzon, Vincent Ongko Wijaya, Abraham Al Jody, Patrick Nalla Nunsio, Ranbebasa Bijak Buana Journal of Infection and Public Health.2022; 15(8): 856. CrossRef
Anti-neuronal antibodies against brainstem antigens are associated with COVID-19 Guglielmo Lucchese, Antje Vogelgesang, Fabian Boesl, Dina Raafat, Silva Holtfreter, Barbara M. Bröker, Angela Stufano, Robert Fleischmann, Harald Prüss, Christiana Franke, Agnes Flöel eBioMedicine.2022; 83: 104211. CrossRef
Post–COVID‐19 Myoclonus–Ataxia Syndrome Responsive to Intravenous Immunoglobulins Massimiliano Godani, Alessandro Beronio, Giuseppe Lanza Movement Disorders Clinical Practice.2022;[Epub] CrossRef
Spectrum of de novo movement disorders in the setting of COVID-19 infection Mitesh Chandarana, Heli Shah, Soaham Desai Annals of Movement Disorders.2022; 5(1): 23. CrossRef
Anti-GAD associated post-infectious cerebellitis after COVID-19 infection Ahmed Serkan Emekli, Asuman Parlak, Nejla Yılmaz Göcen, Murat Kürtüncü Neurological Sciences.2021; 42(10): 3995. CrossRef